Filing summary
Filing and period: The supplied filing is Hywin Holdings Ltd.’s annual report on Form 20-F for the fiscal year ended June 30, 2022—not a 2021 Q4 filing. The company named in the request, Bitventures Ltd, does not match the registrant identified in the filing. Hywin is listed on Nasdaq under HYW; each ADS represents two ordinary shares. Financial figures below are primarily in RMB.
Business context
Hywin is a Cayman Islands holding company operating mainly in China through subsidiaries and contractual arrangements with variable interest entities (VIEs). Its principal business is wealth management for high-net-worth clients; it also provides asset management, insurance brokerage, and health management services. Wealth management generated approximately 97.8% of FY2022 revenue.
Financial and operating performance
| Metric | FY2022 | FY2021 | Change or context |
|---|---|---|---|
| Net revenue | RMB 1,942.1 million | RMB 1,834.4 million | Up 5.9% |
| Income from operations | RMB 326.7 million | RMB 281.6 million | Operating margin was approximately 16.8%, calculated from reported figures |
| Net income | RMB 235.9 million | RMB 207.7 million | Up 13.6%; net margin approximately 12.1% |
| Operating cash flow | RMB 238.8 million | RMB 334.0 million | Down from prior year |
| Investing cash flow | RMB (286.5) million | RMB (14.6) million | Primarily property purchases and Grand Doctor acquisition |
| Cash and cash equivalents | RMB 525.1 million | RMB 439.3 million | 81.2% of FY2022 cash was located in China |
| Restricted cash | RMB 135.2 million | RMB 266.0 million | Mainly client funds held under custody arrangements |
At June 30, 2022, current assets were RMB 1,342.1 million and current liabilities were RMB 779.8 million. The current ratio was approximately 1.72x, calculated from reported figures. Accounts receivable was RMB 564.4 million, with no allowance for doubtful accounts reported. Borrowings were RMB 2.0 million; other liabilities include commissions payable, client deposits, taxes, and acquisition-related payables. The filing states management believed available cash and expected operating cash flow would cover anticipated needs for at least 12 months, while noting possible future financing needs.
Private Market Investment Product transaction value rose to RMB 75.9 billion from RMB 73.0 billion; long-term asset-backed product transaction value fell to RMB 32.0 billion from RMB 45.9 billion, while short-term asset-backed product value rose to RMB 38.7 billion from RMB 24.6 billion. Real-estate-related products represented 37.9% of wealth-management transaction value, down from 58.2%. Active clients increased 15.1% to 43,764; repeat transaction rate was 80.8% versus 76.7%.
Material changes and unusual items
- Revenue growth slowed to 5.9% from 42.8% in FY2021, while net income growth slowed to 13.6% from 95.6%.
- Operating cash flow declined by RMB 95.3 million. The filing attributes FY2022 working-capital movements in part to a decrease in client deposits and changes in commission payables.
- Investing outflows included RMB 232.0 million for buildings and properties and RMB 41.5 million for Grand Doctor. The property acquisition included assumed third-party liabilities; RMB 73.95 million remained payable at year-end.
- Hywin acquired 65.26% of Grand Doctor in January 2022 for stated consideration of RMB 80.5 million. The acquired business contributed RMB 0.4 million of revenue and incurred a RMB 9.4 million net loss after acquisition. The balance sheet included RMB 75.2 million of goodwill and RMB 30.6 million of redeemable noncontrolling interest.
- Subsequent to year-end, the company agreed to acquire stakes in Life Infinity and Sincerity and Compassion for stated considerations of approximately RMB 141.0 million and RMB 55.25 million, respectively.
- The company reported RMB 66.1 million due from a related party, Hywin Financial Holding, at June 30, 2022. These loans were described as unsecured, interest-free, and payable on demand.
Outlook, risks, and controls
The filing provides no specific numerical earnings or revenue guidance. Management described plans to expand asset management, health management, the branch network, and technology capabilities. It also cautioned that the health-management expansion may require significant costs and may continue to operate at a loss. COVID-19 restrictions, China’s property market, product performance, regulation, and client or provider concentration could affect results.
Key structural and regulatory risks include reliance on VIE contracts rather than direct ownership of the China operating entities; evolving PRC rules on foreign listings, cybersecurity, data privacy, and financial services; foreign-exchange and dividend-transfer restrictions; and possible U.S. trading restrictions if PCAOB inspection requirements are not met. Hywin disclosed material weaknesses in financial reporting controls, including insufficient U.S. GAAP and SEC-reporting expertise and inadequate monitoring and documented review controls. Disclosure controls were reported ineffective as of June 30, 2022; remediation was ongoing and not confirmed complete. The independent auditor gave an unqualified opinion on the financial statements but did not opine on internal-control effectiveness.
The filing also identifies historical late or incomplete payment of certain VAT and income taxes; income tax payable was RMB 120.2 million and VAT and other taxes payable were RMB 225.6 million at year-end. The company reported no pending legal proceedings expected to have a material impact and no dividend paid or planned for the foreseeable future.
Important facts for investors to verify
- Confirm the requested issuer and period: this document is Hywin Holdings Ltd.’s FY2022 annual report, not a Bitventures Ltd filing or a 2021 Q4 report.
- Review audited statements and notes for the composition and collectability of receivables, related-party balances, taxes payable, client deposits, and acquisition-related obligations.
- Assess the ongoing remediation of material weaknesses and ineffective disclosure controls, including whether subsequent filings report successful remediation.
- Verify the terms, funding, operating performance, and potential redemption obligations associated with the health-management acquisitions.
- Monitor PRC regulatory developments affecting the VIE structure, overseas listings, cybersecurity and data, and the ability to move cash from China.
- Evaluate continued exposure to real-estate-linked products and reliance on a limited set of product providers and customers.